Replies to post #110012 on Biotech Values

[bladerunner1717]

This is why I, ilpapa, and maybe a few others have been wondering aloud how much trash Teva can talk trash and for how long before they get sued by shareholders if they fail to get approval.

My wonderings exactly. LOLOL And I think this complaint from MNTA puts them on notice, at least, that Sandoz/MNTA is fed up with it.


Bladerunner

[DewDiligence]

Peter’s estimate is off by roughly 2x. Teva’s annualized net profit is about $4.2B*, which means that Teva’s potential after-tax profit from generic Lovenox in the US would at most boost Teva’s EPS by a single-digit %.

*http://sec.gov/Archives/edgar/data/818686/000119312510243894/d6k.htm#tx1102543_1